Gilead Sciences, Inc. (FRA:GIS)

Germany flag Germany · Delayed Price · Currency is EUR
105.90
+4.26 (4.19%)
At close: Oct 17, 2025
4.19%
Market Cap132.59B
Revenue (ttm)24.58B
Net Income (ttm)5.37B
Shares Outn/a
EPS (ttm)4.27
PE Ratio24.67
Forward PE14.73
Dividend2.82 (2.66%)
Ex-Dividend DateSep 15, 2025
Volume120
Average Volume297
Open100.24
Previous Close101.64
Day's Range100.24 - 105.90
52-Week Range78.88 - 111.04
Betan/a
RSI68.01
Earnings DateNov 6, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 17,600
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol GIS
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlan...

2 days ago - Business Wire

Gilead's Trodelvy cuts breast cancer risk by 38% in trial

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on Sunday.

3 days ago - Reuters

Trodelvy Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-f...

3 days ago - Wallstreet:Online

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically m...

3 days ago - Business Wire

Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

3 days ago - Seeking Alpha

Notable Friday Option Activity: RGA, LQDA, GILD

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Reinsurance Group of America, Inc. (Symbol: RGA), where a total of 2,005 contracts have tra...

4 days ago - Nasdaq

Validea Detailed Fundamental Analysis - GILD

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published strateg...

4 days ago - Nasdaq

Insider Sell Alert: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD)

Insider Sell Alert: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD)

5 days ago - GuruFocus

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

5 days ago - Nasdaq

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE: MRK) on Wednesday announced ad...

6 days ago - Benzinga

Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference

Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference

7 days ago - GuruFocus

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV innovat...

7 days ago - Wallstreet:Online

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from Octob...

7 days ago - Business Wire

GILD Quantitative Stock Analysis

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published strateg...

7 days ago - Nasdaq

Noteworthy ETF Outflows: SPMO, GILD, MS, CME

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 Momentum ETF (Symbol: SPMO) where we have detected an ...

8 days ago - Nasdaq

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

Arcus Biosciences reports 26.7-month median survival ... Full story available on Benzinga.com

8 days ago - Benzinga

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic ...

8 days ago - Benzinga

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'

On CNBC's “ Halftime Report Final Trades ,” Rob Sechan , CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ: GILD) as his final trade. Lending support to his choice, Citigroup analyst Geoff M...

8 days ago - Benzinga

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at t...

8 days ago - Business Wire

3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR

With investors on edge as the world's two largest economies go head-to-head again, seeking out stocks that can offer defensive safety in the portfolio may be necessary

11 days ago - Nasdaq

Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase

The Investment Committee give you their top stocks to watch for the second half.

11 days ago - CNBC Television

Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase

The Investment Committee give you their top stocks to watch for the second half.

11 days ago - CNBC

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eas...

12 days ago - Wallstreet:Online

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October ...

12 days ago - Business Wire